Last reviewed · How we verify
RabAvert
At a glance
| Generic name | RabAvert |
|---|---|
| Also known as | active rabies vaccine, RabAver |
| Sponsor | Synermore Biologics Co., Ltd. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults (PHASE3)
- Washington University WU 409: Immune Responses to Rabies Vaccine. (EARLY_PHASE1)
- Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies (PHASE2)
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults (PHASE3)
- Vaccine Responsiveness After CAR-T Cell Therapy (PHASE1)
- A Trial of a Peptide-based Group A Streptococcal (GAS) Vaccine Candidate in Healthy Individuals. (PHASE1, PHASE2)
- A Study of RBI-4000 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |